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INTRODUCTION
Thrombin is a serine protease that interacts with a large number of macromolecular substrates receptors, cofactors and inhibitors that have both procoagulant and anticoagulant properties.
This functional versatility of thrombin is revealed by its structure (1) . Thrombin has the characteristic serine protease fold but differs in having a deep narrow active site cleft occluded by the Leu 45 -Asn 57 (60 insertion loop) and Leu 144 -Gly 155 (149 insertion loop) surface loops.
Unique to thrombin are two cationic surface domains termed anion-binding exosite-I (ABE-I) and -II (ABE-II) important for the binding of ligands to overcome steric hindrance of the occluded active site cleft. ABE-I is important for the binding of fibrinogen (2) (3) (4) , fibrin (5),
heparin cofactor II (6, 7), PAR1 (8, 9) , thrombomodulin (2, (10) (11) (12) and hirudin (13) (14) (15) . ABE-II is important for the binding of platelet glycoprotein Ib (16) , and the glycosaminoglycan bound serpins antithrombin III (6) , heparin cofactor II (6) and protease nexin I (17, 18) .
Both exosites are involved in the binding of coagulation factors V and VIII which is important for the amplification of the coagulation cascade (19) . Studies with the ABE-I specific inhibitor hirugen (19, 20) has implicated the thrombin ABE-I in cleavage of factor V while studies using the ABE-II triple mutant thrombin RA (Arg 89 , Arg 93 , Arg 98 →Ala) has implicated ABE-II (19) . The specific proteolytic cleavage of human factor V (FV) by the serine protease thrombin generates factor Va (FVa) which acts as a cofactor with factor Xa, prothrombin and Ca 2+ ions to form the prothrombinase complex on the surface of anionic phospholipids. This leads to the amplification of the coagulation pathway at the sites of vascular injury. FV, a single chain 330,000 kDa cofactor protein, is activated to FVa with the release of the B domain activation products (E fragment and C1 fragment) by cleavage at the residues Arg 709 , Arg 1018 and membrane via immersion of hydrophobic residues into the laminar membrane core, with direct interactions between the basic C2 domain residues and the negatively charged phosphatidylserine head groups and generalized complementary electrostatic interactions (24).
The heavy chain interacts with prothrombin while both chains interact with factor Xa. As part of the prothrombinase complex, factor Xa has a 300,000 fold increase in catalytic efficiency in thrombin generation from prothrombin (25). (26) .
In this study, we have used 53 mutant thrombins where solvent accessible polar and charged residues were substituted with alanine in order to fully define thrombin residues important in the recognition and cleavage of FV. This would give insights into the roles of the anion binding exosites for specificity towards FV, and residues involved in substrate recognition and cleavage within the active site cleft. 
EXPERIMENTAL PROCEDURES

Materials-Purified human FV and FVa were purchased from Hematologic Technologies
Inc. Factor V deficient plasma and thromboplastin were purchased from Sigma. The expression and purification of wild-type (WT) and alanine substituted mutant thrombins from CHO cells and the mutant R62Q from insect cells, have been described in detail previously (27, 28) . The concentration of active thrombin molecules was determined by titration with D-Phe-Pro-Argchloromethyl ketone (PPACK) using the chromogenic substrate H-D-Val-Leu-Arg-p-nitroanilide (S-2266, Chromogenix, Sweden). The catalytic activity of the purified recombinant WT and mutant thrombins towards H-D-Phe-Pip-Arg-p-nitroanilide (S-2238, Chromogenix, Sweden, fibrinogen, protein C and TAFI has been described (27) .
Activation of Factor V by WT and Mutant
Thrombins-Cleavage assays were performed in 50 µl volumes containing 300 nM human FV and 100 pM thrombin in assay buffer (10 mM Hepes pH 7.4, 150 mM NaCl, 5 mM CaCl 2 and 0.1% PEG 6000 ) at 37˚C for 30 minutes then placed on ice. The concentration of FVa generated in the cleavage assay was determined by a one stage clotting assay. Cleavage reactions were diluted 1000-fold in assay buffer on ice, 50µl
was then added to 50µl of FV deficient plasma and left at room temperature for 10 minutes. The clotting assay was started with 100 µl of thromboplastin (containing 5 mM CaCl 2 , and equilibrated at room temperature) and the clotting reaction was monitored over time at 600 nm in a Softmax™ plate reader (Molecular Dynamics) at room temperature until maximum clotting was achieved (no further change in absorbance at 600 nm). 
RESULTS
Screening for thrombin mutants defective in
Human FV Activation-A site directed mutagenesis strategy was used to determine residues on thrombin important for the interaction between thrombin and human FV necessary for activation of FV to FVa. Fifty-three thrombin mutants (Table 1) , where solvent exposed polar and charged residues were mutated to alanine (27) , were used in a two-stage clotting assay using purified human FV to assay FV activation.
Seventeen thrombin mutants with approximately 50% or less FV activation compared to WT thrombin were identified and mapped to ABE-I, ABE-II, the Leu 45 -Asn 57 insertion loop and the Na + binding loop ( Fig. 1 , Table 2 ). ABE-I had 6 residues (K21A, K65A, H66A, R70A, R73A, K77A) with less than 50% WT activity. Two mutant thrombins showed less than 15% WT activity (R68A, Y71A) ( Fig. 1 , Table 2 ). The double mutant K106A/K107A showed only 24% of the WT type activity, indicating the effects of the single mutations (K106A = 62% and K107A = 52%) were additive for the double mutant. Interestingly, substitution of Arg 62 with glutamine gave a greater decrease in clotting activity (23% WT activity) compared to the alanine substituted form of Arg 62 (65% WT activity). ABE-II showed one mutant (R98A) with greatly reduced FV activation (27% WT activity) while two triple mutants (with a total of 6 residues substituted) showed less than 50% WT activation (R89A/R93A/E94A and R245A/K248A/Q251A). Both the ABE-I and ABE-II mutants have normal k cat /K m values toward the chromogenic substrate S-2238 suggesting the reduced activity is due to impaired binding to the exosites rather than an effect on catalysis ( form part of a surface exposed Na + binding loop which modulates the activity of thrombin (29) .
Mutation of each residue resulted in 5%, 15% and 32% of WT activity respectively.
Interestingly, the E229A mutant shows a (32) . Hence, it is difficult to assess the effect of the substitutions on cleavage at Arg 1545 .
DISCUSSION
Using a total of 53 mutant thrombins, which have a total of 78 alanine substitutions, we were able to map the interaction interface between thrombin and FV using a two-stage clotting assay.
This revealed an extensive binding surface which utilizes ABE-I, ABE-II, the Na + binding loop and the Leu 45 -Asn 57 insertion loop (Fig. 5) .
The ABE-I of thrombin is a surface patch with a high density of surface exposed basic amino acids. This region extends away from the active site cleft and is essential for the binding of fibrinogen (2-4), heparin cofactor II (5,6), PAR1 (8,9), thrombomodulin (2, 10-12) and the inhibitor hirudin (13-15). Binding to ABE-I is important to overcome steric hindrance to the occluded active site. Basic residues in ABE-I have a dual role in binding its many ligands.
Studies with PAR1 (33) and hirudin (34) show that the ABE-I residues contribute to a positive electrostatic field which extends into the solvent. This is important for enhancing the rate of complex formation with complementary electrostatic fields generated by its ligands (electrostatic steering). Secondly, basic residues are used for direct interactions in complex formation (ionic tethering) although which residue involved differs between the various ligands (33, 34) . The ABE-I also has a number of hydrophobic residues important for hydrophobic interactions with PAR1 (9), thrombomodulin (35) and hirudin (14, 15 importance of these three residues has been shown by Esmon and Lollar (19) using the triple thrombin mutant R89A/R93A/R98A which had greatly reduced ability to activate bovine FV.
The residues Arg 89 and Arg 98 lie in close proximity (4Å), while Arg 93 is over 12Å away from these residues (Fig. 5) . Mutation of these residues impairs heparin binding and heparin-ATIII accelerated inhibition of thrombin (41) and Arg 1545 was difficult to determine due to co-migration of the E-fragment and VaL on SDS-PAGE.
Several residues in both ABE-I and ABE-II have reduced FV activation ranging from 52% (K107A) to 65% (R62A). However the magnitude in reduction suggests that these residues are unlikely to participate in major interactions. Mutagenesis studies support the hypothesis that ABE-I basic residues, not involved in direct interactions with hirudin (33) Specificity of the thrombin S 1´ substrate binding site is restricted to small polar P 1ŕ esidues, due in part to occlusion by the Lys 52 side chain (1) . Alanine substitution of this residue resulted in a decrease in FV activation suggesting a role of this residue, and the S 1´ subsite for defining the specificity of thrombin towards FV. Alanine substitution of this residue has also been shown to be important in defining the specificity of thrombin towards antithrombin III (31) and fibrinogen (12, 47 0   10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170 Thrombin Mutants
